These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 26513589)

  • 1. Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study.
    Pallisgaard JL; Lindhardt TB; Hansen ML; Schjerning AM; Olesen JB; Staerk L; Torp-Pedersen C; Gislason GH
    PLoS One; 2015; 10(10):e0141377. PubMed ID: 26513589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study.
    Staerk L; Gislason GH; Lip GY; Fosbøl EL; Hansen ML; Lamberts M; Bonde AN; Torp-Pedersen C; Olesen JB
    Europace; 2015 Aug; 17(8):1215-22. PubMed ID: 25995392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?
    Johansson AK; Juhlin T; Engdahl J; Lind S; Hagwall K; Rorsman C; Fodor E; Alenholt A; Paul Nordin A; Rosenqvist M; Frick M
    Europace; 2015 Oct; 17(10):1514-7. PubMed ID: 26017466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB; Rasmussen LH; Skjøth F; Due KM; Callréus T; Rosenzweig M; Lip GY
    J Am Coll Cardiol; 2013 Jun; 61(22):2264-73. PubMed ID: 23562920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
    Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
    Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
    Berry NC; Mauri L; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP
    Circ Cardiovasc Interv; 2020 Apr; 13(4):e008349. PubMed ID: 32252548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
    Lauffenburger JC; Farley JF; Gehi AK; Rhoney DH; Brookhart MA; Fang G
    J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25862791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia.
    Beshir SA; Chee KH; Lo YL
    Int J Clin Pharm; 2016 Oct; 38(5):1182-90. PubMed ID: 27450507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
    Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
    J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
    Romanelli RJ; Nolting L; Dolginsky M; Kym E; Orrico KB
    Circ Cardiovasc Qual Outcomes; 2016 Mar; 9(2):126-34. PubMed ID: 26812933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation.
    Femia G; Fetahovic T; Shetty P; Lee A
    Heart Lung Circ; 2018 Jul; 27(7):798-803. PubMed ID: 28802808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin.
    Lau WCY; Li X; Wong ICK; Man KKC; Lip GYH; Leung WK; Siu CW; Chan EW
    J Thromb Haemost; 2017 Oct; 15(10):1923-1933. PubMed ID: 28748652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial.
    Nogami A; Harada T; Sekiguchi Y; Otani R; Yoshida Y; Yoshida K; Nakano Y; Nuruki N; Nakahara S; Goya M; Origasa H; Kihara Y; Hirao K; Aonuma K;
    JAMA Netw Open; 2019 Apr; 2(4):e191994. PubMed ID: 31002317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Kidney Injury in Asians With Atrial Fibrillation Treated With Dabigatran or Warfarin.
    Chan YH; Yeh YH; See LC; Wang CL; Chang SH; Lee HF; Wu LS; Tu HT; Kuo CT
    J Am Coll Cardiol; 2016 Nov; 68(21):2272-2283. PubMed ID: 27884245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.
    Go AS; Singer DE; Toh S; Cheetham TC; Reichman ME; Graham DJ; Southworth MR; Zhang R; Izem R; Goulding MR; Houstoun M; Mott K; Sung SH; Gagne JJ
    Ann Intern Med; 2017 Dec; 167(12):845-854. PubMed ID: 29132153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.